First quarter trading update

Group revenue growth with continued profit and margin expansion.

Full year expectations unchanged

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues its scheduled trading update for the three months ("the quarter") ended 31 March 2026.

Elementis will publish its interim results for the six months to 30 June 2026 on 30 July 2026.

Business performance

The Group delivered a strong first quarter performance. On an organic1 basis, Group revenue increased by c.2% and adjusted operating profit and margins grew strongly year-on-year, supported by the continued progress on our self-help initiatives and positive pricing actions.

Personal Care revenue on an organic1 basis improved marginally year-on-year due to higher pricing and improved mix offsetting isolated weaker demand in the Americas. Margins were broadly comparable to Q1 last year.

The integration of Alchemy is progressing in line with our expectations, and we are encouraged by the strong interest shown by customers in Alchemy's products.

Coatings achieved good revenue growth on an organic1 basis year-on-year, driven by higher volumes in Asia that more than offset volume weakness in the Americas, while the Energy business continued to perform strongly, benefiting from operational improvements at our St. Louis plant (US). Margins were up materially year-on-year due to higher cost savings and improved volumes.

The Middle East conflict did not have a material effect on our Q1 performance, and our direct exposure is less than 2% of Group annual revenue. We have responded to higher input costs through pricing actions and expect to fully offset the inflationary impact.

Cash generation in the first quarter was in line with expectations.

Pharma manufacturing business disposal

Further to the announcement on 5 March 2026, the Group continues to make good progress with the sale of its pharma manufacturing business to Associated British Foods with completion expected in Q2 2026 following the receipt of regulatory approvals. Following closing, we expect to return the net cash proceeds to shareholders.

Luc van Ravenstein, CEO of Elementis, said:

"We delivered a strong performance this quarter with higher revenue and profitability, better than management expectations as Elevate Elementis delivers ahead of plan. However, we are mindful of the uncertainty arising from the geopolitical and macroeconomic backdrop, and therefore our current outlook2 for the full year 2026 remains unchanged. Our performance underscores the strength, resilience and differentiated nature of our business model, our local-for-local model, as well as the positive momentum behind our strategy."

• Organic basis means on a continuing constant currency basis and excludes the contribution from acquisitions and disposals including the agreed sale of the pharma manufacturing business which is expected to close in Q2 2026.
• Excluding the pharma manufacturing business.